Top news of the week: 15.03.2023.
Ukraine’s Plea To Industry: Restart Clinical Trials And Give Us New ‘Weapons’ To Fight Cancer
<p>More than one year into the conflict, pharma employees in Ukraine have made heroic efforts to maintain existing clinical studies – but what the country’s <span></span>doctors and CROs ...
Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline
Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion.
Ag & Bioscience Groups: It's Time for Action on Mexico's Biotech Corn Ban
A broad coalition of national and state agriculture and bioscience organizations have written President Biden to thank the administration for beginning technical consultations with Mexico ...
Pfizer Acquires ADC Developer Seagen in $43B Deal
Pfizer is beefing up its oncology portfolio by acquiring ADC pioneer Seagen for a total deal value of $43 billion.
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
Discover the latest news about our company, our products, our policies, and our people.
SVB, biotech’s bank of choice, just failed. It could have ripple effects
Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech companies, failed on Friday. Now biotech startups are left wondering: Who’s going to finance the ...
Analysis: Biotech After SVB's Collapse
The SVB failure appears to have been caused by an underwritten public offering to raise $2.25 billion to cover security losses announced during SVB’s Q1 2023 mid-quarter update.
New therapy for prevention and treatment of COVID-19
A new treatment neutralizes the virus without relying on the patient's own immune system, potentially helping immunocompromised patients.